Company intelligence / Profile preview

Allinno

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Allinno is a biotechnology company that integrates artificial intelligence with traditional drug discovery to develop novel small molecule therapeutics. Based in Shanghai, the company utilizes its proprietary Allinno AI platform to streamline the identification and optimization of drug candidates, focusing primarily on oncology and metabolic diseases. Their research efforts are centered on challenging targets within the ubiquitin-proteasome system and the RAS signaling pathway. Allinno aims to deliver precision medicines that address significant unmet needs in cancer treatment through an efficient, data-driven approach.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Allinno.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allinno.

Explore the full profile